Posted by Michael Wonder on 30 Apr 2020
FDA moving at ‘lightning speed’ on Gilead drug, Commissioner says
30 April 2020 - Several different pathways available for review, Hahn says.
The FDA is moving at “lightning speed” to review data on Gilead Sciences Inc.’s experimental COVID-19 treatment remdesivir, Commissioner Stephen Hahn said, after encouraging results emerged from a key U.S. trial.
“We’re working with the company to emphasise the necessity of speed while at the same time to understand the data,” Hahn said in an interview. “There will be a lot of factors that go into all the regulatory decisions. We want to look at the totality of data to make sure that remdesivir is targeted to the right patients.”
